Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration

Opthea Limited's OPT OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. 

  • The data presented was a prespecified subgroup analysis of a Phase 2b dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD).
  • Sixty-six participants (18%) with Polypoidal Choroidal Vasculopathy (PCV) out of a total study population of 366 were included in the analysis. 
  • OPT-302 combination therapy had a safety profile consistent with the standard of care anti-VEGF-A monotherapy while demonstrating greater improvements in best-corrected visual acuity (BCVA) and less retinal fluid than ranibizumab monotherapy. 
  • The +6.7 letters comparative superiority of 2 mg OPT-302 combination therapy over ranibizumab (p = 0.0253) was accompanied by a greater improvement in secondary vision and anatomical outcome measures at week 24.
  • Price Action: OPT shares closed at $6.65 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralAge-Related Macular DegenerationBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!